About MindImmune Therapeutics

MindImmune Therapeutics is developing a therapeutic antibody that targets the peripheral immune system to mitigate the immune attack on the brain associated with Alzheimer’s disease. This approach aims to address the underlying pathology of Alzheimer’s by preventing neuroinflammation and preserving cognitive function.

```xml <problem> Alzheimer's disease is characterized by an immune system attack on the brain, leading to neuroinflammation and cognitive decline. Current treatments do not adequately address the underlying immune-related pathology of the disease. </problem> <solution> MindImmune Therapeutics is developing a novel therapeutic antibody that targets the peripheral immune system to mitigate the immune attack on the brain associated with Alzheimer’s disease. By blocking this immune assault, the therapy aims to reduce neuroinflammation and preserve cognitive function. The company's approach is based on the understanding that the nervous and immune systems are integrated, and that targeting the immune system can offer a new avenue for treating brain diseases like Alzheimer's. The antibody is designed to act peripherally, preventing immune cells from infiltrating the brain and causing further damage. </solution> <features> - Novel therapeutic antibody targeting the peripheral immune system. - Designed to block the immune attack on the brain in Alzheimer's disease. - Aims to reduce neuroinflammation. - Seeks to preserve cognitive function. </features> <target_audience> The primary target audience includes individuals at risk of or diagnosed with Alzheimer's disease, as well as their caregivers and healthcare providers. </target_audience> ```

What does MindImmune Therapeutics do?

Where is MindImmune Therapeutics located?

MindImmune Therapeutics is based in Kingston, Jamaica.

When was MindImmune Therapeutics founded?

MindImmune Therapeutics was founded in 2016.

How much funding has MindImmune Therapeutics raised?

MindImmune Therapeutics has raised 14150000.

Location

Kingston, Jamaica

Founded

2016

Funding

14150000

Employees

13 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

MindImmune Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

mindimmune.com 300+

Crunchbase

Founded 2016 – Kingston, Jamaica

Funding

Estimated Funding

$10M+

Team (10+)

No team information available.

Company Description

Problem

Alzheimer's disease is characterized by an immune system attack on the brain, leading to neuroinflammation and cognitive decline. Current treatments do not adequately address the underlying immune-related pathology of the disease.

Solution

MindImmune Therapeutics is developing a novel therapeutic antibody that targets the peripheral immune system to mitigate the immune attack on the brain associated with Alzheimer’s disease. By blocking this immune assault, the therapy aims to reduce neuroinflammation and preserve cognitive function. The company's approach is based on the understanding that the nervous and immune systems are integrated, and that targeting the immune system can offer a new avenue for treating brain diseases like Alzheimer's. The antibody is designed to act peripherally, preventing immune cells from infiltrating the brain and causing further damage.

Features

Novel therapeutic antibody targeting the peripheral immune system.

Designed to block the immune attack on the brain in Alzheimer's disease.

Aims to reduce neuroinflammation.

Seeks to preserve cognitive function.

Target Audience

The primary target audience includes individuals at risk of or diagnosed with Alzheimer's disease, as well as their caregivers and healthcare providers.